Avita Medical

267 articles about Avita Medical

• AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance

  2/23/2023

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the fourth quarter and full-year ended December 31, 2022.

• AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance

  2/9/2023

  AVITA Medical, Inc. announced that it will report its fourth quarter and full year 2022 financial results after the close of the U.S. financial markets on Thursday, February 23, 2023.

• AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call

  1/19/2023

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical” or the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today changes to its management structure designed to advance its strategic growth plans and accelerate execution under recently appointed Chief Executive Officer, James Corbett

• AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo

  12/19/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RECELL® System.

• AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders

  12/13/2022

  AVITA Medical, Inc., a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced the results of its 2022 Annual Meeting of Stockholders, which was held virtually on December 12, 2022 .

• AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair

  12/12/2022

  AVITA Medical, Inc. announced today the submission of a Premarket Approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA) for the company’s RECELL ® System.

• AVITA Medical® to Present at the Piper Sandler 34th Annual Healthcare Conference

  11/21/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today that its management team will present at the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022, at 4:30 p.m. Eastern Time.

• AVITA Medical® to Host Investor Webinar Briefing

  11/16/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, CEO, and Michael Holder, CFO, on November 23, 2022 at 4:00pm (PST) / November 24, 2022 at 11:00am (AEDT).

• AVITA Medical Reports Third Quarter 2022 Financial Results

  11/10/2022

  AVITA Medical, Inc. reported financial results for the third quarter ended September 30, 2022.

• AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair

  11/9/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) today announced achievement of co-primary endpoints as a result of updated analysis of data from its clinical trial evaluating the safety and effectiveness of the RECELL® System for soft tissue repair.

• AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System

  11/3/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced today that the Food and Drug Administration (FDA) granted the RECELL System designations as a Breakthrough Device for its proposed soft tissue repair indication as well as its vitiligo indication.

• AVITA Medical to Announce Third Quarter 2022 Financial Results

  10/20/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced today that it will report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022.

• AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer

  9/28/2022

  AVITA Medical, Inc. announced the appointment of James Corbett as Chief Executive Officer, effective immediately.

• Investor Webinar Briefing - September 13, 2022

  9/13/2022

  AVITA Medical, Inc. invites shareholders and prospective investors to attend its investor webinar and presentation by Dr. Mike Perry, CEO, and Michael Holder, CFO, on September 20, 2022 at 3:30pm / September 21, 2022 at 8:30am.

• AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System

  9/12/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company) today announced positive topline results from a pivotal randomized, controlled trial evaluating the safety and effectiveness of the RECELL® System for repigmentation of stable vitiligo lesions.

• RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns

  9/1/2022

  AVITA Medical, Inc. announced that COSMOTEC, an M3 Group Company, received insurance coverage in Japan for the RECELL® System for the treatment of acute burns.

• RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting

  8/17/2022

  AVITA Medical, Inc. announced that a poster presentation on cell characterization and potential clinical benefits of the RECELL® Autologous Cell Suspension System for the treatment of stable vitiligo will be shared at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting.

• AVITA Medical Reports Second Quarter 2022 Financial Results

  8/11/2022

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, reported financial results for its second quarter ended June 30, 2022.

• AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL® System

  8/11/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), today announced topline results from its pivotal randomized, controlled trial evaluating the safety and effectiveness of the RECELL System combined with meshed autograft for reduction of donor skin harvesting in soft tissue reconstruction.

• AVITA Medical to Announce Second Quarter 2022 Financial Results

  7/25/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it will release its second quarter 2022 financial results on Thursday, August 11, 2022.